抄録
Lung transplantation is the ultimate treatment for irreversible end-stage pulmonary diseases. The histopathologic standardized grading scheme of cellular rejection for pulmonary allograft has been developed by the International Society for Heart and Lung Transplantation (ISHLT) and is now broadly accepted. The acute antibody-mediated rejection (AMR) has been highlighted at the Banff meeting in recent years, and increased attention has also been paid to it in regard to pulmonary allograft. However, AMR in lung transplantation has been debatable, and histopathologic and immunophenotypic criteria were adopted as not yet being established. In thise paper we present the recommendation of clinicopathologic findings possibly associated with AMR in lung allograft.
